The stock fell 11.0% after earnings, signaling investor disappointment despite the U.S. approval and European regulatory progress. The excerpt highlights ambitious expansion plans and early launch execution but provides no launch or financial metrics, leaving commercial uptake and the outlook unclear.
Shares rose modestly by 2.2% following the quarter, reflecting investor acknowledgment of meaningful progress in pancreatic cancer programs and regulatory milestones, although the reaction suggests some caution remains on near-term commercial ramp or broader pipeline clarity.